Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review

T Regulatory Cells in Allergy and Health: A Question of Allergen Specificity and Balance

Taylor A. · Verhagen J. · Akdis C.A. · Akdis M.

Author affiliations

Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland

Related Articles for ""

Int Arch Allergy Immunol 2004;135:73–82

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: July 08, 2004
Accepted: July 30, 2004
Published online: September 22, 2004
Issue release date: September 2004

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Anergy, tolerance and active suppression may not be independent events, but rather involve similar mechanisms and cell types in immune regulation. Induction of allergen-specific regulatory/suppressor T cells (TReg) seems essential for the maintenance of a healthy immune response to allergens. Allergen-specific immunotherapy can induce specific TReg cells that abolish allergen-induced proliferation of T helper 1 (Th1) and Th2 cells, as well as their cytokine production. TReg cells utilize multiple suppressive mechanisms, interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) as secreted cytokines and CTLA-4, PD-1, mTGF-β, mIL-10, TGF-βR and IL-10R as surface molecules. An important aspect of TReg cells is the regulation of antibody isotypes and suppression of proinflammatory cells. IL-10 and TGF-β secreted by TReg cells skew production of IgE towards the noninflammatory isotypes, IgG4 and IgA, respectively. Furthermore, TReg cells may directly or indirectly suppress effector cells of allergic inflammation such as basophils and eosinophils. In conclusion, induction of antigen-specific TReg cells may redirect an inappropriate immune response against allergen or autoantigens with the help of a broad range of suppressor mechanisms.

© 2004 S. Karger AG, Basel


References

  1. Schwartz RH: T cell anergy. Annu Rev Immunol 2003;21:305–334.
  2. Walker LS, Abbas AK: The enemy within: Keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002;2:11–19.
  3. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldman M: Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434–1447.
  4. Faith A, Akdis CA, Akdis M, Simon H-U, Blaser K: Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56lck and ZAP-70 tyrosine kinase activities. J Immunol 1997;159:53–60.
  5. Schwartz RH: T cell anergy. Annu Rev Immunol 2003;21:305–334.
  6. Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227–257.
  7. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:142–146.
  8. Corry DB: IL-13 in allergy: Home at last. Curr Opin Immunol 1999;11:610–614.
  9. Ying S, Meng Q, Barata LT, Robinson DS, Durham SR, Kay AB: Associations between IL-13 and IL-4 (mRNA and protein), vascular cell adhesion molecule-1 expression, and the infiltration of eosinophils, macrophages, and T cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Immunol 1997;158:5050–5057.
  10. Kotowicz K, Callard RE, Klein NJ, Jacobs MG: Interleukin-4 increases the permeability of human endothelial cells in culture. Clin Exp Allergy 2004;34:445–449.
  11. Trautmann A, Schmid-Grendelmeier P, Krüger K, Crameri R, Akdis M, Akkaya A, Bröcker E-B, Blaser K, Akdis AC: T cells and eosinophils cooperate in the induction of bronchial epithelial apoptosis in asthma. J Allergy Clin Immunol 2002;109:329–337.
  12. Trautmann A, Akdis M, Brocker EB, Blaser K, Akdis CA: New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. Trends Immunol 2001;22:530–532.
  13. Yssel H, Groux H: Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol 2000;121:10–18.
  14. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237–1240.
  15. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–742.
  16. Cottrez F, Hurst SD, Coffman RL, Groux H: T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000;165:4848–4853.
  17. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
  18. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K: Role of IL-10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
  19. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis AC: IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–1214.
  20. Akdis M, Simon H-U, Weigl L, Kreyden O, Blaser K, Akdis CA: Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999;163:466–475.
  21. Abernathy-Carver KJ, Sampson HA, Picker LJ, Leung DYM: Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J Clin Invest 1995;95:913–918.
  22. Klunker S, Trautmann A, Akdis M, Verhagen J, Schmid-Grendelmeier P, Blaser K, Akdis AC: A second step of chemotaxis after transendothelial migration: Keratinocytes undergoing apoptosis release IP-10, Mig and iTac for T cell chemotaxis towards epidermis in atopic dermatitis. J Immunol 2003;171:1078–1084.
  23. Gutierrez-Ramos JC, Lloyd C, Kapsenberg ML, Gonzalo JA, Coyle AJ: Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000;177:31–42.
  24. Akdis M, Trautmann A, Klunker S, Daigle I, Kücüksezer UC, Deglmann W, Disch R, Blaser K, Akdis CA: T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 2003;17:1026–1035.
  25. Simon H-U, Blaser K: Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia. Immunol Today 1995;16:53–55.
  26. Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, Ray A, Homer RJ, Cohn L: Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002;27:593–602.
  27. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brokker EB, Blaser K, Akdis CA: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106:25–35.
  28. Akdis CA, Blaser K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy. FASEB J 1999;13:603–609.
  29. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, Blaser K: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676–1683.
  30. Gershon RK, Kondo K: Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology 1970;18:723–737.
  31. Green DR, Webb DR: Saying the ‘S’ word in public. Immunol Today 1993;14:523–525.
  32. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001;166:5530–5539.
  33. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603–616.
  34. Nasser SM, Ying S, Meng O, Kay AB, Ewan PW: Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001;31:3704–3713.
  35. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK: Type 1 T regulatory cells. Immunol Rev 2001;182:68–79.
  36. Müller UR, Akdis CA, Fricker M, Akdis M, Bettens F, Blesken T, Blaser K: Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998;101:747–754.
  37. Weiner HL: Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207–214.
  38. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.
  39. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–1164.
  40. Shevach EM: CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389–400.
  41. Wood KJ, Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199–210.
  42. Read S, Powrie F: CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644–649.
  43. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG: Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 2002;32:2237–2245.
  44. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295–302.
  45. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S: Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 2002;196:379–387.
  46. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS: Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608–615.
  47. Ke Y, Kapp JA: Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol 1996;156:916–921.
  48. Weiner HL: Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997;48:341–351.
  49. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H: Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004;5:516–523.
  50. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway CA Jr, Weiner HL: Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388–391.
  51. Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, Marboe C, Mancini D, Cortesini R, Suciu-Foca N: Alloantigen specific CD8+CD28– FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004;16:1055–1068.
  52. Strober S, Cheng L, Zeng D, Palathumpat R, Dejbakhsh-Jones S, Huie P, Sibley R: Double negative (CD4–CD8– alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev 1996;149:217–230.
  53. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L: Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000;6:782–789.
  54. Hanninen A, Harrison LC: Gamma delta T cells as mediators of mucosal tolerance: The autoimmune diabetes model. Immunol Rev 2000;173:109–119.
  55. Seo N, Tokura Y, Takigawa M, Egawa K: Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999;163:242–249.
  56. Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA: Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 1997;158:3610–3618.
  57. Seymour BW, Gershwin LJ, Coffman RL: Aerosol-induced immunoglobulin (Ig)-E unresponsiveness to ovalbumin does not require CD8+ or T cell receptor (TCR)-gamma/delta+ T cells or interferon (IFN)-gamma in a murine model of allergen sensitization. J Exp Med 1998;187:721–731.
  58. Mauri C, Gray D, Mushtaq N, Londei M: Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489–501.
  59. Reid CD: The biology and clinical applications of dendritic cells. Transfus Med 1998;8:77–86.
  60. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk A: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772–4780.
  61. Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725–731.
  62. Morganti-Kossmann MC, Kossmann T, Brandes ME, Mergenhagen SE, Wahl SM: Autocrine and paracrine regulation of astrocyte function by transforming growth factor-beta. J Neuroimmunol 1992;39:163–173.
  63. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ: Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003;170:3806–3811.
  64. Rivas JM, Ullrich SE: Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992;149:3865–3871.
  65. Lidstrom C, Matthiesen L, Berg G, Sharma S, Ernerudh J, Ekerfelt C: Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: Implications for suppressor macrophages in decidua. Am J Reprod Immunol 2003;50:444–452.
  66. Dowdell KC, Cua DJ, Kirtkman E, Stohlman SA: NK cells regulate CD4 responses prior to antigen encounter. J Immunol 2003;171:234–239.
  67. Kitamura M, Suto T, Yokoo T, Shimizu F, Fine LG: Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996;156:2964–2971.
  68. Müller UR, Mosbech H: Position paper: Immunotherapy with hymenoptera venoms. Allergy 1993;48:36–46.
  69. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Lowenstein H, Muller U, Norman PS, Reisman RE, Valenta R, Valovirta E, Yssel H: Allergen immunotherapy: Therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401–405.
  70. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265–269.
  71. Bousquet J: Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30(suppl 1):2–5.
  72. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J, Zak-Nejmarrk T, Koga R, Kobayashi T, Blaser K, Akdis AC: Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420–425.
  73. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944–2952.
  74. Rocklin RE, Sheffer A, Greineder DK, Melmon KL: Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213–1219.
  75. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM, Lichtenstein LM, Norman PS: Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76:2247–2253.
  76. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187–4194.
  77. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123–2130.
  78. Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–475.
  79. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131–1139.
  80. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747–754.
  81. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM: Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998;101:506–513.
  82. Oldfield WL, Larche M, Kay AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 2002;360:47–53.
  83. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–151.
  84. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM: PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32:634–643.
  85. Durham SR, Till SJ: Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157–164.
  86. Punnonen J, De Waal Malefyt R, Van Vlasselaer P, Gauchat J-F, De Vries JE: IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280–1289.
  87. Sonoda E, Matsumoto R, Hitoshi Y, Ishii T, Sugimoto M, Araki S, Tominaga A, Yamaguchi N, Takatsu K: Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 1989;170:1415–1420.
  88. Walker C, Virchow J-C, Bruijnzeel PLB, Blaser K: T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991;146:1829–1835.
  89. Schleimer RP, Derse CP, Friedman B, Gillis S, Plaut M, Lichtenstein LM, MacGlashan DW Jr: Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids. J Immunol 1989;143:1310–1327.
  90. Treter S, Luqman M: Antigen-specific T cell tolerance down-regulates mast cell responses in vivo. Cell Immunol 2000;206:116–124.
  91. Shim YK, Kim BS, Cho SH, Min KU, Hong SJ: Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003;33:52–57.
  92. Marshall JS, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M: Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 1996;97:1122–1128.
  93. Schandane L, Alonso-Vega C, Willems F, Gerard C, Delvaux A, Velu T, Devos R, de Boer M, Goldman M: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994;152:4368–4374.
  94. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S: Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996;97:1288–1296.
  95. Koning H, Neijens HJ, Baert MR, Oranje AP, Savelkoul HF: T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine 1997;9:427–436.
  96. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J: Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;103:326–332.
  97. Hellings PW, Vandenberghe P, Kasran A, Coorevits L, Overbergh L, Mathieu C, Ceuppens JL: Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol 2002;32:585–594.
  98. Haneda K, Sano K, Tamura G, Shirota H, Ohkawara Y, Sato T, Habu S, Shirato K: Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation. A novel high-dose tolerance in the trachea. Am J Respir Cell Mol Biol 1999;21:268–274.
  99. Hansen G, McIntire JJ, Yeung VP, Berry G, Thorbecke GJ, Chen L, DeKruyff RH, Umetsu DT: CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000;105:61–70.
  100. Joffre O, Gorsse N, Romagnoli P, Hudrisier D, van Meerwijk JP: Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood 2004;103:4216–4221.
  101. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823–832.
  102. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211–5218.
  103. Battaglia A, Ferrandina G, Buzzonetti A, Malinconico P, Legge F, Salutari V, Scambia G, Fattorossi A: Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire. Immunology 2003;110:304–312.
  104. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstain B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–612.
  105. Antony PA, Restifo NP: Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy. J Immunother 2002;25:202–206.
  106. Turner J, Gonzalez-Juarro M, Ellis DL, Basaraba RJ, Kipnis A, Orme IM, Cooper AM: In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002;169:6343–6351.
  107. Casaulta C, Schoni MH, Weichel M, Crameri R, Jutel M, Daigle I, Akdis M, Blaser K, Akdis CA: IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis. Pediatr Res 2003;53:313–319.
  108. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL: The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001;194:1497–1506.
  109. Redpath S, Ghazal P, Gascoigne NR: Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9:86–92.
  110. Bartram U, Speer CP: The role of transforming growth factor beta in lung development and disease. Chest 2004;125:754–765.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: July 08, 2004
Accepted: July 30, 2004
Published online: September 22, 2004
Issue release date: September 2004

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.